

# Two-state selection of conformation-specific antibodies

Junjun Gao<sup>a</sup>, Sachdev S. Sidhu<sup>1,b</sup>, and James A. Wells<sup>a,2</sup>

<sup>a</sup>Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, 1700 4th Street, San Francisco, CA 94143; and <sup>b</sup>Department of Protein Engineering, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080


Communicated by Robert M. Stroud, University of California, San Francisco, CA, December 22, 2008 (received for review October 19, 2008)

We present a general strategy for identification of conformation-specific antibodies using phage display. Different covalent probes were used to trap caspase-1 into 2 alternative conformations, termed the on-form and the off-form. These conformation-trapped forms of the protease were used as antigens in alternating rounds of selection and antiselection for antibody antigen-binding fragments (Fabs) displayed on phage. After affinity maturation, 2 Fabs were isolated with  $K_D$  values ranging from 2 to 5 nM, and each bound to their cognate conformer 20- to 500-fold more tightly than their noncognate conformer. Kinetic analysis of the Fabs indicated that binding was conformation dependent, and that the wild-type caspase-1 sits much closer to the off-form than the on-form. Bivalent IgG forms of the Fabs were used to localize the different states in cells and revealed the activated caspase-1 is concentrated in a central structure in the cytosol, similar to what has been described as the pyroptosome. These studies demonstrate a general strategy for producing conformation-selective antibodies and show their utility for probing the distribution of caspase-1 conformational states *in vitro* and in cells.

allostery | caspase-1 | phage display | protein conformational change

Protein allostery is a central means to regulate protein function in cells. Allostery is mediated through conformational selection upon binding of different small molecules, biopolymers, or metal ions or through posttranslational modifications. Structural methods give us high-resolution insight into the nature of these conformational transitions *in vitro* but have limited use for determining the equilibrium distribution of these states in solution or in cells. To expand the tools useful for trapping and analyzing conformational states in enzymes, both in solution and in cells, we developed a general strategy for 2-state selection of conformation-specific antibodies using phage display.

As a test case, we focused on caspase-1, an aspartate-specific thiol protease that is critical for processing of proinflammatory cytokines during the innate immune response (for review, see refs. 1–3). The enzyme is produced as an inactive proenzyme that exists primarily as a monomer in solution (4, 5). Upon innate immune stimuli, the proenzyme is believed to dimerize by binding to scaffolding proteins known collectively as the inflammasome. This triggers proteolytic autoactivation or transactivation, in which the propeptide and an intersubunit linker are cleaved (6, 7). Crystal structures of the mature protease with various small molecules bound show that it can exist in at least 2 conformations (8–10). When an active site inhibitor is bound, the enzyme appears to be in a catalytically competent form (called the on-form) (9). However, binding of covalent disulfide ligand to a central cavity  $\approx 15$  Å from the active site stabilizes the protease in an inactive state (called the off-form) (8). This allosterically inhibited state is virtually identical to the apo-form of the enzyme as seen in the crystal structures. The dimeric enzyme shows positive cooperativity [ $n_{\text{hill}} = 1.5$  (8)], and mutational studies reveal that only a small set of residues (a “hot-wire”) mediates the on-to-off transition between the allo-



**Fig. 1.** Model and labeling design. (A) Proposed model for the dynamic activation of caspase-1. It has been suggested that in cells procaspase-1 exists primarily as monomer. Upon binding to scaffolding proteins (NALPs, ASC, etc.), procaspase-1 dimerizes and undergoes proteolytic activation. Mature caspase-1 is in equilibrium between off- and on-conformations. Binding of ligands at the active or allosteric site can shift the equilibrium toward the on- or off-state. (B) Covalent labeling of apo-caspase-1. Irreversible active-site inhibitors or allosteric compounds were used to trap caspase-1 into a stable conformation for antibody selection.

steric and active sites (11). These data support a dynamic activation model for caspase-1 (Fig. 1A).

We wished to generate monoclonal antibodies to each of the on- and off-states to better understand the equilibrium distribution of these states in solution and in cells and to provide probes to localize these forms in cells. We trapped homogeneous forms of the on- and off-states of caspase-1 using the active site inhibitor (Ac-YVAD-cmk) to lock the on-state and compound 34 (1-methyl-3-trifluoromethyl-1H-thieno[2,3-c]pyrazole) to lock the off-state. These conformation-locked forms of caspase-1 were then used as antigens in sorting codon-restricted phage display libraries (12) to generate high-affinity antibody

Author contributions: J.G., S.S.S., and J.A.W. designed research; J.G. performed research; S.S.S. contributed new reagents/analytic tools; J.G., S.S.S., and J.A.W. analyzed data; and J.G., S.S.S., and J.A.W. wrote the paper.

The authors declare no conflict of interest.

<sup>1</sup>Present address: Banting and Best Department of Medical Research and the Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada M5S 3E1.

<sup>2</sup>To whom correspondence should be addressed: jim.wells@ucsf.edu.


This article contains supporting information online at [www.pnas.org/cgi/content/full/0812952106/DCSupplemental](http://www.pnas.org/cgi/content/full/0812952106/DCSupplemental).

© 2009 by The National Academy of Sciences of the USA










**Fig. 6.** Inhibition of caspase-1 by IgG<sub>off</sub> in THP-1 extracts. LPS-stimulated THP-1 cell extracts were incubated with IgGs at 4 °C overnight and probed by Western blot analysis using an antibody specific for mature IL-1 $\beta$  (Cell Signaling).

To investigate whether the antibodies have similar effects on caspase-1-mediated cleavage in cells, we examined the processing of pro-IL-1 $\beta$ , a well characterized natural caspase-1 substrate, in the presence of each of the 2 IgGs. THP-1 cells were stimulated by LPS for 4 h to increase pro-IL-1 $\beta$  expression, and cell extract was prepared as described (7). Western blots probed for mature IL-1 $\beta$  showed that IgG<sub>off</sub> significantly blocked caspase-1-mediated cleavage of pro-IL-1 $\beta$  (Fig. 6). IgG<sub>on</sub> also inhibited processing of pro-IL-1 $\beta$  but to a lesser extent possibly by sterically blocking the larger protein substrate binding. These results suggest that IgG<sub>off</sub> can effectively inhibit caspase-1 activity in cells by sequestering the enzyme in the off-state.

**Localization of Active Caspase-1 Conformer in Cells.** The ability of IgG<sub>on</sub> to bind selectively to the on-form of caspase-1 and not to procaspase-1 makes it potentially useful for tracking caspase-1 activation in cells. THP-1 cells can be differentiated into macrophages with PMA treatment, which then become adherent to glass coverslips. After fixation and mild detergent permeabilization, IgG<sub>on</sub> was added as the probe for the on-state of caspase-1. Immunofluorescent microscopy revealed that most of cells stimulated with LPS/ATP showed a general increase in diffuse fluorescent signal (Fig. S3). Intriguingly,  $\approx 10\%$  of these cells contained a single bright, near-spherical structure located in the cytosol (Fig. 7). That we observed this structure only when staining with IgG<sub>on</sub> and not with IgG<sub>off</sub> suggests it is highly enriched for the on-state of caspase-1.



**Fig. 7.** Probing active conformers of caspase-1 in THP-1 cells. LPS-stimulated THP-1 cells were stained with DAPI (A) and IgG<sub>on</sub> (B). The merged image is shown in C. Note the spherical body found in  $\approx 10\%$  of cells.

## Discussion

We present a general strategy for directly obtaining conformation-selective antibodies that was applied to study distributions of on- and off-conformers of caspase-1. The differences in conformation for the on- and off-states as viewed by X-ray crystallography are relatively modest. Thus, that high-affinity antibodies specific for the 2 states could be isolated suggests the wide applicability of this strategy.

The key elements of this approach are the availability of ligands to trap specific conformations of the protein of interest coupled with an *in vitro* selection method to isolate specific binding proteins. Although we used covalent ligands to lock specific conformations, one could also employ noncovalent ligands, so long as one worked at a high enough concentration to maintain saturation. It should also be possible to trap these alternate target conformations with natural protein-binding partners or using engineered disulfide or chemical cross-linkers.

State-selective binding partners have been identified before. It has been reported that using phage display to isolate peptides specific for estradiol- or tamoxifen-activated estrogen receptor (20). Fabs have also been selected for GTP-bound Ras (21). However, neither study selected for more than 1 state. Recent elegant work by Grutter and coworkers (22) has shown that it is possible to isolate conformation-specific binding proteins to caspase-2 without using conformation-trapped antigens. However, this approach required the assaying of  $>100$  individual clones following selections from a combinatorial library of designed ankyrin repeat proteins (DARPin) to identify the allosteric inhibitors.

*In vitro* selection allowed antiselection in solution (23) with the noncognate form of the protein, which enabled the dramatic enrichment of selective binders. Although we found phage display to be particularly effective in *in vitro* selection, there are a variety of other methods one could apply, including ribosome display, yeast display, and others (for review, see refs. 24 and 25). Fab display is particularly effective, because it is well established for naive selections and has been made even more effective recently by using codon-restricted CDR libraries enriched for Ser and Tyr residues (12, 14). However, there is a variety of other scaffolds that could be potentially used, such as DARPins (26), Affibodies (27), fibronectin type III domains (28), zinc finger DNA-binding domains (29), and many others. Moreover, one could imagine using this approach to identify conformation-selective antibodies to other biopolymers such as alternate forms of DNA or RNAs such as riboswitches, etc.

Our data suggest that the Fabs we identified are specific for the conformers of caspase-1 they were selected for. First, at the selection stage, we found strong enrichments for the specific antigen used in the selection, and binders survived the antiselection steps with noncognate antigens. The consensus se-

quences for the Fab<sub>on</sub> and Fab<sub>off</sub> were very different from each other, and they bound to their cognate antigen with 20- to 500-fold higher affinity than to the noncognate forms. Strong evidence for conformational specificity was provided by the SPR data, which showed that the increased affinity for the cognate antigen was due to a faster on-rate rather than a slower off-rate. Interestingly, the fact that the antibodies can bind to the noncognate form at all suggests each of the inhibitor-locked antigens is dynamic, albeit the inhibitor-locked cognate conformer is much more populated than the noncognate conformer. In addition, both Fabs did not cross-react with caspase-4 and -5, which have the highest sequence similarity to caspase-1 (Fig. S4). We do not know the exact epitopes where these Fabs bind on caspase-1. However, it is very unlikely their epitopes include the inhibitor itself. In fact, the structure of the inhibitor was alternated during positive selection to avoid antibodies that interacted directly with the inhibitor.

The binding kinetics of these Fabs to the apo form of caspase-1 suggests strongly that the enzyme in solution is dynamically interchanging between conformations because the affinity for Fabs is intermediate between the locked forms of caspase-1 (Fig. 3B). However, the apo enzyme sits overwhelmingly in the off-form. For example, the enzyme binds with an affinity that is much closer to the locked off-form of caspase-1 than to the on-form. The ratios of  $K_D$  values for the Fab<sub>off</sub> to Fab<sub>on</sub> vary >4 logs; the unlabeled caspase-1 is within 1 log unit of the locked-off form yet 3 log units away from the locked-on form of caspase-1. Thus, the average ensemble of conformations for apo caspase-1 is intermediate between the on- and off-states but populates the off- over the on-state by a factor of  $\approx 1,000$ . It is noteworthy that X-ray structures show the conformation of the apo-form of caspase-1 (9) is virtually identical to the off-form generated by the allosteric tethered ligand (8).

The Fab fragments have marked functional effects on the apo caspase-1 that are consistent with previous reports that the enzyme exhibits positive cooperativity (8, 11). The titration of apo-caspase-1 with Fab<sub>on</sub> causes >3-fold activation of activity (Fig. 4A) probably by binding and stabilizing the active conformer. Moreover, the  $EC_{50}$  for activation by Fab<sub>on</sub> (11 nM) is significantly lower than the  $K_D$  for binding (300 nM; Fig. 4B). These data suggest that the presence of substrate can stabilize the active conformer and thus improve apparent affinity. Likewise, Fab<sub>off</sub> inhibits the enzyme. The  $IC_{50}$  for inhibition (920 nM) is significantly above the  $K_D$  for binding of Fab<sub>off</sub> (5 nM) and reflects the fact that substrate stabilizes the on-form and thus competes for binding of Fab<sub>off</sub>. We previously showed that labeling caspase-1 with Ac-YVAD-cmk and the allosteric inhibitor are mutually exclusive: binding of the active site inhibitor promotes a conformation that is incompatible with binding of the allosteric inhibitor and vice versa (8). Similarly the Fabs appear to bind to mutually exclusive conformations and away from these inhibitor binding sites. Thus, the enzyme can be allosterically activated or inhibited through binding of conformation-specific antibodies on different surfaces.

One of the advantages of using Fabs is that they are readily converted into IgGs that allow one to study possible avidity effects. Interestingly, the IgG<sub>off</sub> bound 40 times tighter than Fab<sub>off</sub> to apo-caspase-1, whereas IgG<sub>on</sub> bound with nearly identical affinity to Fab<sub>on</sub>. This may reflect the different position of the binding epitope on caspase-1 and resultant stoichiometry such that 1 IgG<sub>off</sub> molecule can bind to both subunits of caspase-1 simultaneously, whereas 1 IgG<sub>on</sub> molecule cannot. The enhancement in affinity seen for IgG<sub>off</sub> for Fab<sub>off</sub> is almost entirely due to enhanced on-rate, which may reflect that the dimer has a greater probability of productive binding per collision.

Previous studies indicate that procaspase-1 is monomeric (4, 30), yet very little is known about the conformation of this form

in vitro or in cells. We find the IgG<sub>off</sub> binds modestly to procaspase-1 but neither IgG<sub>on</sub> nor Fab<sub>on</sub> nor Fab<sub>off</sub> bind detectably (Fig. 5A). This suggests that the pro-form is much closer to the off-form of caspase-1 in conformation and that dimerizing procaspase-1 by binding to IgG<sub>off</sub> promotes a conformation more like that of apo caspase-1. Nonetheless, the pro-form has a conformation that is not identical to the off-form because IgG<sub>off</sub> bound to procaspase with a  $K_D$  of 130 nM compared with binding to caspase-1 with a  $K_D$  of 0.38 nM. These results were mirrored in the immunoprecipitation experiments (Fig. 5B). The IgG<sub>off</sub> can pull down both procaspase-1 and caspase-1 in THP-1 cells, whereas IgG<sub>on</sub> can pull down only the mature form.

The additional advantage for converting the Fabs to IgGs was that these can be used with standard immunostaining reagents to localize specific conformations of caspase-1 in cells. In THP-1 cells probed with IgG<sub>off</sub>, we saw only diffuse staining of the cells whether stimulated with LPS or not (data not shown). In contrast, when THP-1 cells were treated with LPS and stained with IgG<sub>on</sub>, we found intense staining of a single supermolecular cytosolic structure (1–2  $\mu$ m in diameter) in  $\approx 10\%$  of the cells. Alnemri and coworkers have reported the existence of a virtually identical supermolecular structure, which they termed the pyroptosome, in 15–30% of THP-1 cells stimulated with LPS using GFP-tagged ASC (apoptosis-associated speck-like protein containing a CARD domain) (30). That we can stain the supermolecular structure only with IgG<sub>on</sub> not IgG<sub>off</sub> suggests strongly that virtually all of the caspase-1 is processed to the mature form and rests in the active conformation in the pyroptosome-like structure. This would indicate that caspase-1 is either actively catalyzing proteolysis, or perhaps more likely that binding to the ASC scaffold stabilizes the on-form of caspase-1. In this regard, ASC may function like the on-state antibody; however, its binding site does not overlap with that of IgG<sub>on</sub>.

Overall, these studies demonstrate a general approach for selecting binding proteins to specific protein conformations using small molecule ligands to lock conformations of interest and phage display to identify conformation-selective antibodies. The Fabs and IgG derivatives were useful for defining and localizing the specific forms of caspase-1 in vitro and in cells. Moreover, this approach could be useful for generating specific inhibitors or even activators of proteins in cells extracts and possibly in cells by using appropriate intracellular antibody delivery technology (31, 32).

## Materials and Methods

**Caspase-1 Expression and Purification.** The p20 subunit (residues 120–279) and p10 subunit (residues 317–404) of wild-type human caspase-1 were separately expressed in *E. coli* as inclusion bodies from a pRSET expression vector (Invitrogen). The purification and refolding of protein from inclusion bodies was performed as described (8). The Cys285Ala mutant of caspase-1 was made by refolding Cys285Ala mutated p20 with wild-type p10 inclusion bodies. A form of procaspase-1 lacking the CARD domain (CARDless procaspase, residues 120–404) was cloned into a pET23b expression vector (Novagen) with a C-terminal His<sub>6</sub> tag and transformed into *E. coli* BL21(DE3) strain. The expression was induced with 0.2 mM IPTG induction for 20 min at  $OD_{600} \approx 0.6$ . Cell pellets were lysed by 5 passes through a microfluidizer in ice-cold lysis buffer (100 mM Tris, pH 8.0, 100 mM NaCl). The lysate was cleared by centrifugation at  $48,500 \times g$  for 15 min at 4 °C. The supernatant was first loaded on a 5-mL HisTrap HP column (GE Healthcare), and bound protein was eluted with a 0- to 200-mM imidazole gradient after washing. The eluate were diluted into 20 mM Tris, pH 8.0, 5% glycerol, and loaded on a 5-mL HiTrap Q HP column. The p32 was eluted with a 0- to 0.5-M NaCl gradient and aliquots were frozen immediately in an ethanol-dry ice bath.

**Caspase-1 Labeling.** To prepare the on-form caspase-1, wild-type caspase-1 was incubated with 4-fold excess of active-site inhibitor (Ac-YVAD-cmk or z-WEHD-fmk) at 4 °C overnight in the labeling buffer (50 mM Hepes, pH 8.0, 200 mM NaCl, 50 mM KCl, 200  $\mu$ M  $\beta$ -ME). Protein precipitate was removed by centrifugation, and the labeling was confirmed by the mass shift observed by

LC-MS (Waters). To prepare the off-form of caspase-1, a catalytic-inactive caspase-1 Cys285Ala was incubated with 150  $\mu$ M of the allosteric inhibitor [compound 34 or compound 11 (8)] at 4 °C overnight in the same labeling buffer containing 1 mM  $\beta$ -ME. For random biotinylation, the off-form of caspase-1 was incubated with 15-fold excess sulfo-NHS-LC-biotin (Pierce) for 45 min at ambient temperature, and the reaction was stopped by buffer exchange using a NAP-25 column (GE Healthcare).

**Library Construction and Sorting.** We modified the Fab-template phagemid (pV-0116c) (12) to have TAA stop codons in all 3 heavy chain CDRs and the light chain CDR-L3 to reduce wild-type Fab background. For the construction of naïve libraries, the resulting phagemid was used as the “stop template” in a mutagenesis reaction with oligonucleotides designed to repair simultaneously the stop codons and introduce designed mutations at the desired sites, as described (16).

In sorting for on-form specific Fabs, the phage pool was cycled through rounds of binding selection with the active conformer of caspase-1 that was directly immobilized on 96-well Maxisorp plate (Thermo Fisher). Bound phage were eluted with 100 mM HCl and neutralized with 1 M Tris, pH 8.0. Phage were amplified in *E. coli* XL1-blue (Stratagene) with the addition of M13-KO7 helper phage (New England Biolabs). In sorting for the off-form specific Fabs, a solution-phase binding strategy was adapted for better control over the selection and anti-selection process. The phage pool was incubated for 2 h at room temperature with biotinylated allosteric conformer before being captured on neutravidin or streptavidin (Pierce) coated Maxisorp plates. The bound phage were then eluted and propagated as described above. After selection, individual clones were picked and grown in a 96-well deep well plate with 2YT broth supplemented with carbenicillin and M13-KO7. The culture supernatants were used in phage ELISAs to identify binding clones (33).

**Antibody Purification and Kinetic Analysis by SPR.** The phage display phagemid was converted into the Fab expression vector by deleting the sequence encoding for the CP3 minor phage coat protein and inserting a  $\lambda$  terminator sequence (GCTCGGTTGCCCGCGGCTTTTAT) downstream of the stop codon at the end of C<sub>H1</sub> domain. Fab protein was secreted from *E. coli* 34B8 strain transformed with individual plasmids in low-phosphate medium at 30 °C for 26 h, as described (18). To generate IgG proteins, the variable domains were subcloned into vectors designed for transient IgG expression in

CHO cells (18). Fab proteins were purified with protein A affinity chromatography and IgG proteins were purified with protein G affinity chromatography.

Kinetic binding analyses were performed by surface plasmon resonance (SPR) using a BIAcore 3000 (GE Healthcare). Ligand-bound or free caspase-1 dimers were immobilized on CM5 chips and serial dilutions of Fabs or IgGs were injected. Binding responses on flow cells with immobilized caspase-1 variants were corrected by subtraction of responses on a blank reference flow cell. A 1:1 Langmuir model in BIAevaluation software (GE Healthcare) was used for fitting the sensograms and the  $K_D$  values were calculated from the ratios of  $K_{off}/K_{on}$ .

**Immunoprecipitation from THP-1 Cell Extracts.** THP-1 cells were grown to a density of  $1 \times 10^6$  cell/ml and harvested by centrifugation at  $150 \times g$  for 5 min. Cells were lysed by Dounce homogenizer in ice-cold buffer (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1 mM Na-EDTA, 1 mM Na-EGTA, 0.1 mM PMSF, and the Roche protease inhibitor mixture). Cell lysates were cleared by centrifugation at  $500 \times g$ ,  $3,000 \times g$ , and  $22,000 \times g$  for 10 min each. Aliquots were incubated with or without IgGs overnight at 4 °C and immunocomplexes were recovered by protein-G agarose beads. Presence of pro-caspase-1 and caspase-1 were visualized by Western blot analysis.

**Immunofluorescence Microscopy.** THP-1 cells were grown to the density of  $5 \times 10^5$  cell/ml and differentiated with 0.5  $\mu$ M PMA for 3 h and allowed to attach to no. 1½ glass coverslips overnight. Cells were treated with 1 mM LPS for 2 h followed by 5 mM ATP for 30 min before fixation and mild detergent permeabilization. After blocking with 10% BSA for 1 h, IgG<sub>on</sub> was added at 100  $\mu$ M concentration for 1 h. After 3 washes with PBS + 0.1% Triton X-100, the cells were stained for 1 h with Alexa Fluor 488 conjugated goat anti-human IgG antibody (Invitrogen). Cells were washed 3 times and mounted with ProLong Gold containing DAPI (Invitrogen). Images were recorded on a Nikon 6D High-Throughput Microscope equipped with a Photometrics Coolsnap HQ2 Camera.

**ACKNOWLEDGMENTS.** We thank S. Birtalan, Y. Zhang, B. Li, G. Fuh, J. Scheer, V. Chiang, and Y. Chen for advice and assistance. We also thank the Protein Engineering Department and the sequencing, oligonucleotide synthesis, and fermentation teams at Genentech for generous support, as well as K. Thorn and the Nikon Imaging Center at University of California, San Francisco, for help with immunofluorescence microscopy. This work was supported by National Institutes of Health Grant 5R01AI070292-02 and the Sandler Family Foundation gift (to J.A.W.).

1. Ting JP, Willingham SB, Bergstralh DT (2008) NLRs at the intersection of cell death and immunity. *Nat Rev Immunol* 8:372–379.
2. Petrilli V, Dostert C, Muruve DA, Tschopp J (2007) The inflammasome: A danger sensing complex triggering innate immunity. *Curr Opin Immunol* 19:615–622.
3. Dinarello CA (2007) Mutations in cryopyrin: Bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. *Arthritis Rheum* 56:2817–2822.
4. Faustini B, et al. (2007) Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. *Mol Cell* 25:713–724.
5. Boatright KM, et al. (2003) A unified model for apical caspase activation. *Mol Cell* 11:529–541.
6. Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: Intracellular regulators of infection and inflammation. *Nat Rev Immunol* 7:31–40.
7. Martinon F, Burns K, Tschopp J (2002) The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-1beta. *Mol Cell* 10:417–426.
8. Scheer JM, Romanowski MJ, Wells JA (2006) A common allosteric site and mechanism in caspases. *Proc Natl Acad Sci USA* 103:7595–7600.
9. Romanowski MJ, Scheer JM, O'Brien T, McDowell RS (2004) Crystal structures of a ligand-free and malonate-bound human caspase-1: Implications for the mechanism of substrate binding. *Structure* 12:1361–1371.
10. Rano TA, et al. (2008) An allosteric circuit in caspase-1. *J Mol Biol* 381:1157–1167.
11. Datta D, Scheer JM, Romanowski MJ, Wells JA (2008) An allosteric circuit in caspase-1. *J Mol Biol* 381:1157–1167.
12. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a 4-amino-acid code: A dominant role for tyrosine in antigen recognition. *Proc Natl Acad Sci USA* 101:12467–12472.
13. Birtalan S, et al. (2008) The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. *J Mol Biol* 377:1518–1528.
14. Fellouse FA, et al. (2005) Molecular recognition by a binary code. *J Mol Biol* 348:1153–1162.
15. Deshayes K, et al. (2002) Rapid identification of small binding motifs with high-throughput phage display: Discovery of peptidic antagonists of IGF-1 function. *Chem Biol* 9:495–505.
16. Sidhu SS, Lowman HB, Cunningham BC, Wells JA (2000) Phage display for selection of novel binding peptides. *Methods Enzymol* 328:333–363.
17. Jackson JR, Sathe G, Rosenberg M, Sweet R (1995) In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta. *J Immunol* 154:3310–3319.
18. Lee CV, et al. (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. *J Mol Biol* 340:1073–1093.
19. Johnson G, Wu TT (2000) Kabat database and its applications: 30 years after the first variability plot. *Nucleic Acids Res* 28:214–218.
20. Norris JD, et al. (1999) Peptide antagonists of the human estrogen receptor. *Science* 285:744–746.
21. Horn IR, Wittinghofer A, de Bruine AP, Hoogenboom HR (1999) Selection of phage-displayed fab antibodies on the active conformation of ras yields a high affinity conformation-specific antibody preventing the binding of c-Raf kinase to Ras. *FEBS Lett* 463:115–120.
22. Schweizer A, et al. (2007) Inhibition of caspase-2 by a designed ankyrin repeat protein: Specificity, structure, and inhibition mechanism. *Structure* 15:625–636.
23. Li B, et al. (1995) Minimization of a polypeptide hormone. *Science* 270:1657–1660.
24. Gai SA, Wittrup KD (2007) Yeast surface display for protein engineering and characterization. *Curr Opin Struct Biol* 17:467–473.
25. Lipovsek D, Pluckthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. *J Immunol Methods* 290:51–67.
26. Binz HK, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. *Nat Biotechnol* 22:575–582.
27. Nord K, et al. (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. *Nat Biotechnol* 15:772–777.
28. Koide A, Koide S (2007) Monobodies: Antibody mimics based on the scaffold of the fibronectin type III domain. *Methods Mol Biol* 352:95–109.
29. Cho GS, Zostak JW (2006) Directed evolution of ATP binding proteins from a zinc finger domain by using mRNA display. *Chem Biol* 13:139–147.
30. Fernandes-Alnemri T, et al. (2007) The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. *Cell Death Differ* 14:1590–1604.
31. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. *Proc Natl Acad Sci USA* 96:11723–11728.
32. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 23:1126–1136.
33. Sidhu SS, et al. (2004) Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. *J Mol Biol* 338:299–310.
34. Kabat EA, et al. (1987) *Sequences of Proteins of Immunological Interest*, 4th Ed (National Institutes of Health, Bethesda).